Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07616063

Subjective Assessment of Spatial Orientation Abilities in Alzheimer's Disease

Difficulty orienting oneself and finding one's way around the environment, also known as "topographical disorientation" (TD) or "spatial disorientation" (SD), is a common and often early symptom of Alzheimer's disease (AD) that affects people's independence and well-being. Being able to identify it is therefore crucial in order to provide appropriate support.

It cannot be assessed using conventional psychometric tests due to its low ecological validity. Several subjective assessment scales have been created to screen for SD "spatial disorientation" and assess its functional and psychological impact. However, none of these scales have been translated and validated in French. As a result, DS is not assessed in routine clinical practice.

Among these scales, the Wayfinding Questionnaire (WQ) explores three dimensions: spatial orientation, distance estimation, and spatial anxiety. This questionnaire has undergone psychometric validation studies in its original Dutch version for a population with mild post-stroke , and norms for the general population have been published.

Our team translated this questionnaire into French (i.e., "Questionnaire d'Orientation Spatiale" (QOS)) and adapted it cross-culturally to preserve the qualities of the measurement. A "Caregiver" version was also created, taking into account the anosognosia known to occur in AD. Primary Objective : Evaluate the psychometric properties of the Spatial Orientation Questionnaire (SOSQ) (i.e., the French translation and adaptation of the Wayfinding Questionnaire) in assessing spatial orientation disorders in patients with Alzheimer's disease, in both its "patient" and "caregiver" versions. Secondary objective : Evaluate the acceptability of the Spatial Orientation Questionnaire (SOC) in its "patient" and "caregiver" versions.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Alzheimer s Disease Behavior Orientation, Spatial Spatial Behavior Spatial Orientation

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHRU (Centre Hospitalier Régionale Universitaire) Nancy

Nancy, 54500, France

Location contact

Hajar EL AKHDAR

CONTACT

[email protected]

+33 3 83 15 35 96

Thérèse JONVEAUX, Dr

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For all subjects :

  • Native French speakers
  • Independent mobility: (minimum mobility range of 3 (i.e., neighborhood) on the LSA-F assessment of the mobility zone scale)
  • Person affiliated with a social security system or beneficiary of such a system

Patients (Subgroup A1) and healthy control subjects (Group C):

  • Individuals who have received complete information about the clinical research organization and have signed their written informed consent
  • Patients (Subgroups A2 and A3) and Companions (Group B) Individuals who have received complete information about the clinical research and have agreed to participate

Patients (group A):

  • Aged 55 to 85
  • Diagnosis of probable Alzheimer's disease (NINCDR-ADRDA diagnostic criteria)
  • Score of 4 or less on the Hachinski Ischemic Scale
  • Score of 20 or higher on the Folstein MMSE (Mini Mental State Examination)
  • In the case of specific treatment for Alzheimer's disease (anticholinesterase and memantine treatments), treatment stability for > 15 days
  • Able to walk independently, i.e., without assistance, whether human or technical, except for a simple cane

Caregivers (group B):

  • Caregivers of a person with dementia included in group A, with regular contact (at least 10 hours per week, spread over a minimum of 3 times per week)
  • Healthy control subjects (group C):
  • Aged 55 to 85
  • Able to walk independently, i.e., without assistance, whether human or technical, except for a single cane
  • Normal performance on the Folstein Mini-Mental State Examination (MMSE), according to GRECO (Cognitive Assessment Task Force) standards

Exclusion criteria

For all subjects:

  • Adults subject to legal protection measures (guardianship, curatorship, judicial protection)
  • Adults unable to give their consent
  • Persons deprived of their liberty by judicial or administrative decision, persons receiving psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1.
  • Persons capable of giving consent but unable to read French
  • Persons capable of giving consent but unable to write
  • One of the members of the patient/caregiver dyad refusing to participate in the study.

Patients (subgroup A1) and healthy control subjects (group C):

  • Sensory or phasic deficit interfering with the task.
  • History of moderate or severe head trauma (with loss of consciousness).
  • Change in psychotropic treatment less than 48 hours before the tests
  • Chronic alcoholism
  • Severe depression (score greater than or equal to 10 on the GDS-15 Geriatric Depression Scale)
  • Presence of other clinically significant psychiatric or neurological conditions (except Alzheimer disease for case subjects)

Treatment and study plan

Questionnaire d'Orientation Spatiale (QOS)

Diagnostic Test

French version of the wayfinding questionnaire

Primary outcomes

  1. French version of the QOS Score

    Time frame: Baseline and between 30 and 90 days after baseline for groups A1, A2, A3, B1 and B2

    There are three sub-scores in total :

    • "Navigation and Orientation" sub-score (sum of items 1, 2, 3, 6, 7, 13, 15, 16, 17, 18, 19)
    • "Distance estimation" sub-score (sum of items 4, 5, 14)
    • "Spatial anxiety" subs-core (sum of the reversed scores for items 8, 9, 10, 11, 20, 21, 22, 12)

    For these three sub-scores, a high score indicates a good level of spatial orientation.

Study contacts

Contact information is provided by the study sponsor or research team.

EL AKHDAR Hajar, Master Science

CONTACT

[email protected]

0383153596

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Official study title

Evaluation Subjective Des CApacités d'Orientation sPatialE Dans la mAladie D'Alzheimer

Acronym: ESCAPE-AD

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 29, 2026
Registry last updated
May 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.